Wilmington, North Carolina 28401


Purpose:

Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy


Criteria:

Inclusion Criteria: - 18 years and older - HEPLISAV-B exposure within 28 days prior to conception or at any time during pregnancy Exclusion Criteria: - Less than 18 years of age - HEPLISAV-B exposure greater than 28 days prior to conception


NCT ID:

NCT03664648


Primary Contact:

Deborah Covington, PhD
Phone: 1-844-443-7734
Email: heplisavbpregnancyregistry@ppdi.com


Backup Contact:

Email: rhyer@dynavax.com
Randall Hyer, MD
Phone: (510) 848- 5100


Location Contact:

Wilmington, North Carolina 28401
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.